Publikationsserver der Universitätsbibliothek Marburg

Titel:Diagnostic Impact of Dual-Time PET/CT with 68Gallium-PSMA in Prostate Cancer and 68Gallium-DOTATOC in Neuroendocrine Tumors
Autor:Librizzi, Damiano
Weitere Verfasser:Eilsberger, Friederike; Ottenthaler, Stefan; Ebrahimifard, Ali; Luster, Markus; Yousefi, Behrooz H.
Veröffentlicht:2023
URI:https://archiv.ub.uni-marburg.de/es/2024/0286
DOI: https://doi.org/10.3390/biomedicines11041052
DDC:610 Medizin
Publikationsdatum:2024-01-15
Lizenz:https://creativecommons.org/licenses/by/4.0

Dokument

Schlagwörter:
dual-time, prostate cancer, 68gallium, PSMA, DOTATOC, PET/CT, neuroendocrine tumor

Summary:
Background: The timing of imaging for 68gallium (68Ga)-PSMA and 68Ga-DOTATOC are stated to be around 60 min post-injection (p.i.). In some lesions, late imaging (3–4 h p.i.) showed advantages. The aim of our evaluation was to demonstrate the relevance of an “early” late acquisition. Methods: We retrospectively evaluated 112 patients who underwent 68Ga-DOTATOC-PET/CT and 82 patients who underwent 68Ga-PSMA-PET/CT. The first scan was acquired 60 min (±15 min) after application. In cases of diagnostic ambiguity, a second scan was performed 30–60 min later. Pathological lesions were analyzed. Results: Almost half of all 68Ga-DOTATOC cases and about one-third of all 68Ga-PSMA examinations showed a change in findings due to the second acquisition. In total, 45.5% of neuroendocrine tumor (NET) patients and 66.7% of prostate cancer (PCa) patients showed relevant TNM classification changes. For 68Ga-PSMA, there were significant increases in sensitivity and specificity from 81.8% to 95.7% and from 66.7% to 100%, respectively. Statistically significant improvements in sensitivity (from 53.3% to 93.3%) and specificity (from 54.6% to 86.4%) were demonstrated for NET patients. Conclusion: Early second images can improve diagnostics with 68Ga-DOTATOC and 68Ga-PSMA PET/CT.


* Das Dokument ist im Internet frei zugänglich - Hinweise zu den Nutzungsrechten